News & Updates
Filter by Specialty:
KEYNOTE-240 4.5-year follow-up supports pembrolizumab’s role in 2L advanced HCC treatment
An extended 4.5-year follow-up of the phase III KEYNOTE-240 trial showed that pembrolizumab continued to provide clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), with a manageable safety profile, vs placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC).
KEYNOTE-240 4.5-year follow-up supports pembrolizumab’s role in 2L advanced HCC treatment
11 Nov 2022
Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer
Among prostate cancer patients on androgen deprivation therapy (ADT), a small prostate and higher reductions in testosterone levels appear to aggravate storage symptoms, a recent study has found.
Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer
10 Nov 2022
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
10 Nov 2022
Nursing interventions boost sexual QoL of breast cancer patients
Nursing interventions such as psychological and educational assistance help improve the sexual quality of life (QoL) among patients with breast cancer, reports a recent study.
Nursing interventions boost sexual QoL of breast cancer patients
10 Nov 2022
T-cell exhaustion tied to post-BCG recurrence in bladder cancer
In patients with non-muscle-invasive bladder cancer (NMIBC), high-grade (HG) recurrence after bacillus Calmette-Guérin (BCG) treatment is associated with T-cell exhaustion, according to a study.
